Contineum Therapeutics, Inc. (CTNM)
This price reflects trading activity during the overnight session on the Blue Ocean ATS, available 8 PM to 4 AM ET, Sunday through Thursday, when regular markets are closed.
Trading disclosure
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Learn moreKey Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
|
Mr. Carmine N. Stengone MBA, MS
|
President, CEO & Director | 1.12M | -- | 1976 |
|
Mr. Peter T. Slover CPA
|
Chief Financial Officer | 737.63k | -- | 1975 |
|
Dr. Timothy R. Watkins M.D., M.Sc.
|
Chief Medical Officer & Head of Development | 778.77k | -- | 1974 |
|
Ms. Morgan Paulsen
|
Senior Manager of Accounting | -- | -- | -- |
|
Dr. Daniel S. Lorrain Ph.D.
|
Chief Science Officer | 565.02k | -- | 1969 |
|
Mr. Steve E. Kunszabo
|
Senior Director of Investor Relations & Corporate Communications | -- | -- | -- |
|
Mr. John S. Healy
|
General Counsel & Corporate Secretary | 612.78k | -- | 1972 |
|
Mr. Austin Chen Ph.D.
|
Senior VP & Head of Research | -- | -- | -- |
|
Ms. Julie S. Iwashita
|
Senior Vice President of Clinical Operations | -- | -- | -- |
|
Ms. Kristina Haeckl Rac
|
Senior Vice President of Regulatory Affairs | -- | -- | -- |
Contineum Therapeutics, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 51
Description
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States. The company's lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and chronic pain. It also develops PIPE-307, a novel, small-molecule inhibitor of the muscarinic type 1 receptor for depression and relapse-remitting multiple sclerosis. The company was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. Contineum Therapeutics, Inc. was incorporated in 2009 and is based in San Diego, California.
Corporate Governance
Upcoming Events
November 2, 2026 at 9:00 PM UTC
Contineum Therapeutics, Inc. Earnings Date
